EASL Podcasts

The following objectives will be addressed in this EASL Deep Dive episode:

• Have a profound knowledge of the pitfalls, limitations and difficulty of interpretation of the different tests of copper metabolism and liver copper assessments
• Be able to establish a diagnostic approach to Wilson’s disease, integrating clinical, laboratory, genetic and imaging tools
• Have a good understanding of the different treatment modalities, how to position them in the disease course, how to monitor treatment and what to expect as a result/outcome?

This EASL DeepDive webinar is supported by Orphalan and Univar Solutions. Orphalan and Univar Solutions have had no input into the content of this EASL DeepDive.

Steatotic liver disease (SLD) research relies heavily on preclinical models, yet no single model can fully capture the complexity of human disease. In this episode, we explore the new EASL position paper on preclinical SLD models. From MASLD and MetALD to organoids and precision-cut liver slices, we discuss the strengths, limitations, and translational relevance of today's most widely used models. How do we choose the right model, and are we any closer to finding the perfect one?

Based on EASL position paper on preclinical models of steatotic liver disease

Host: Rui Castro (University of Lisbon) 
Speakers: Mathias Heikenwälder (University of Tübingen) and Suchira Gallage (University of Tübingen)

This episode is also available on EASL Campus: https://easlcampus.eu/tltm/episode-11

This programme is intended for health care professionals only and is provided for educational purposes. EASL does not endorse or promote any medicinal products or medical devices. The views and opinions expressed are those of the speakers and do not necessarily reflect those of EASL. 

All declarations of conflicts of interest are listed on EASL Campus (https://easlcampus.eu/tltm/episode-11).

EASL is not responsible for the accuracy of any translated versions of this podcast or of subtitles generated automatically by artificial intelligence.

Haemochromatosis remains one of the most common inherited metabolic disorders, yet it is frequently underdiagnosed and inconsistently managed in clinical practice. With widespread use of iron studies and genetic testing, clinicians are increasingly faced with questions around interpretation, penetrance, and clinical significance. In this podcast, we explore current challenges in diagnosis and management, focusing on who should be tested, how to interpret results, and which patients benefit from intervention in modern hepatology practice. 

Host: Thomas Marjot (King's College, London)
Speakers: John Ryan (Beaumont Hospital, Dublin) and Heinz Zoller (Medical University of Innsbruck)

This episode is also available on EASL Campus: https://easlcampus.eu/tltm/episode-10

In this episode, we discuss the first pig-to-human liver xenotransplantation and the breakthroughs behind the revival of xenotransplantation, examining its potential and remaining challenges. We also explore the accelerating field of machine perfusion, clarifying different approaches and reviewing the evidence supporting their role in organ assessment, optimisation, and DCD utilisation.

Host: Sarwa Darwish Murad (Erasmus University Rotterdam)
Speakers: Jeroen de Jonge (Erasmus University Rotterdam) and Matthew Armstrong (University Hospital Birmingham)

This episode is also available on EASL Campus: https://easlcampus.eu/tltm/episode-09

Spontaneous bacterial peritonitis (SBP) remains a major complication of cirrhosis - but rising antimicrobial resistance and emerging data are challenging long-standing practices.

In this episode, we review current evidence on primary and secondary prophylaxis, resistance patterns, albumin use, and treatment strategies. How should clinicians balance prevention with antimicrobial stewardship? And where might practice need to evolve in 2026?

Host: Thomas Marjot (King's College London)
Speakers:  Bogdan Procopet (Institute of Gastroenterology and Hepatology, Cluj-Napoca) and Alastair O'Brien (Royal Free Hospital, London) 

This episode is also available on EASL Campus: https://easlcampus.eu/tltm/episode-08

In this EASL DeepDive webinar, the expert panel presents and explains the key studies behind the latest recommendations included in the EASL Clinical Practice Guidelines on the management of extrahepatic cholangiocarcinoma.

Learning Objectives

• To identify patients at risk for eCCA, and review the current tools and strategies for its surveillance, diagnosis, staging, and classification
• To define the optimal candidates for resection and liver transplantation, and discuss challenges in the surgical management of eCCA
• To discuss the role of systemic therapy in the management of eCCA across all disease stages (including neoadjuvant, adjuvant, and palliative settings)

Faculty

• Luca Maroni - Moderator
• Julie Heimbach - Speaker
• Anna Saborowski - Speaker
• Lars Aabakken - Speaker

This episode explores the role of lifestyle in preventing and managing liver disease, including MASLD/MASH. Our experts discuss the impact of diet and physical activity, why lifestyle change can be difficult to start and sustain, and why small, achievable steps can still make a meaningful difference. 

Host: Cyrielle Caussy
Speakers:  Kate Hallsworth and Manuel Romero-Gómez 

This episode is also available on EASL Campus: https://easlcampus.eu/tltm/episode-07

In this EASL DeepDive, experts will discuss the latest advances in the EASL Clinical Practice Guidelines on the management of hepatitis B virus infection, published in the "Journal of Hepatology" in 2025.

Learning objectives

• Understand the updated EASL recommendations for initiating and discontinuing antiviral therapy in chronic hepatitis B, including key differences with other HBV guidelines. Participants will be able to identify treatment indications and make informed decisions about when and how to stop antiviral therapy.
• Learn how to monitor patients with hepatitis B across different clinical scenarios, including those not on treatment, those receiving antiviral therapy, surveillance for hepatocellular carcinoma, risk of reactivation, and response to vaccination, in alignment with the new EASL guidelines.
• Explore future directions in the management of chronic hepatitis B as outlined in the EASL guidelines, including advances in nomenclature and antiviral therapies under development.

Faculty

• Markus Cornberg - Moderator
• Maud Lemoine - Speaker
• Sabela Lens - Speaker
• Jerzy Jaroszewicz - Speaker

In this EASL DeepDive, experts will discuss the latest advances in the EASL Clinical Practice Guidelines on the management of autoimmune hepatitis, published in the "Journal of Hepatology" in 2025.

Learning objectives

• Select induction and maintenance treatment strategies aimed at achieving complete biochemical response
• Recognise and manage disease flares, treatment intolerance, and suboptimal response in autoimmune hepatitis
• Understand tailored approaches to autoimmune hepatitis management in specific patient groups

Faculty

• Mária Papp - Moderator
• Michael Heneghan - Speaker
• George Dalekos - Speaker
• Maria Carlota Londoño - Speaker

Hepatocellular carcinoma (HCC) is responsible for 75% of all primary liver cancers and is the third most prevalent cause of cancer death worldwide, with 900,000 new cases diagnosed each year. Many patients are diagnosed at an advanced stage, making curative treatment difficult.

In this DeepDive Webinar, you’ll be guided through the latest advances in hepatocellular carcinoma management, from the rising impact of immunotherapy combinations to evolving approaches in intermediate-stage disease. 

This EASL DeepDive webinar is supported by Bayer AG. Bayer AG has had no input into the content of this EASL DeepDive.

Learning Objectives

• What are strategies to optimise surveillance and early diagnosis of hepatocellular carcinoma
• What are the optimal candidates for surgery (including liver transplantation) and locoregional therapies (alone or combined with immunotherapy)
• Optimal selection of systemic front-line regimens and treatment sequencing after first-line immunotherapy

Faculty

• Manon Allaire - Moderator
• Fabio Piscaglia - Speaker
• Antonio D'Alessio - Speaker
• Anna Saborowski - Speaker